Bothrops erythromelas is a snake of medical importance responsible for most of the venomous incidents in Northeastern Brazil. However, this species is not included in the pool of venoms that are used in the Brazilian polyvalent bothropic antivenom (BAv) production. Furthermore, it is well known that antivenom therapy has limited efficacy against venom-induced local effects, making the search for complementary alternatives to treat snakebites an important task. Jatropha gossypiifolia is a medicinal plant widely indicated in folk medicine as an antidote for snakebites, whose effectiveness against Bothrops jararaca venom (BjV) has been previously demonstrated in mice. In this context, this study assessed the effectiveness of the aqueous extract (AE) of this plant and of the BAv against local effects induced by B. erythromelas venom (BeV). Inhibition of BeV-induced edematogenic and hemorrhagic local effects was assayed in mice in pre-treatment (treatment prior to BeV injection) and post-treatment (treatment postenvenomation) protocols. Inhibition of proteolytic, phospholipase A 2 (PLA 2 ) and hyaluronidase enzymatic activities of BeV were evaluated in vitro. BAv cross-reactivity and estimation of antibody titers against BeV and BjV were assessed by Ouchterlony double diffusion test. The results show that in pretreatment protocol AE and BAv presented very similar effects (about 70% of inhibition for edematogenic and 40% for hemorrhagic activities). However, BAv poorly inhibited edema and hemorrhage in post-envenomation protocol, whilst, in contrast, AE was significantly active even when used after BeV injection. AE was able to inhibit all the tested enzymatic activities of BeV, while BAv was active only against hyaluronidase activity, which could justify the low effectiveness of BAv against BeV-induced local effects in vivo. Ouchterlony's test showed positive cross-reactivity against BeV, but the antibody titers were slightly higher against BjV. Together, these data indicate that despite the presence of immunological cross-reactivity, Brazilian polyvalent bothropic antivenom presented low inhibitory potential against biological and enzymatic effects of BeV, illustrating the need for new strategies in the production of antivenom with broad neutralizing potential in the treatment of Bothrops spp. envenomation throughout the country. Together, the results highlight the antiophidic potential of J. gossypiifolia, Abbreviations: AE, aqueous leaf extract of Jatropha gossypiifolia; ANOVA, analysis of variance; AUC 0e2h , area under the time-course curves after 2 h; BAv, bothropic antivenom; BeV, Bothrops erythromelas venom; BjV, Bothrops jararaca venom; CGEN, Brazilian Genetic Heritage Management Council; CIOMS, Council of International Organizations of Medical Sciences; CONCEA, National Council for the Control of Animal Experimentation of Brazil; DAMP, damage-associated molecular pattern; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; HEK-293, human embryonic kidney 293 cells; IL, interleukin; MPO, myeloperoxidase; PBS, phosphate buffered saline; PLA 2 , phospholipase A 2 ; SDS-PAGE, polyacrylamide gel electrophoresis with sodium dodecil sulphate; SEM, standard error of mean; SISBIO, Brazilian Biodiversity Authorization and Information System; SVMP, snake venom metalloproteinase; TNF-a, tumor necrosis factor alpha.
suggesting that it can be considered a potential adjuvant in the treatment of bothropic envenomation local effects.
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Introduction
Snake envenoming is a serious public health problem in many regions around the world. In 2013e2015, the Bothrops snakes caused about 87% of snakebites that occurred in Brazil (Brasil, 2016) . Bothropic envenomation is characterized by immediate and intense local effects (edema, hemorrhage and necrosis, which can often lead to permanent disabilities), cardiovascular alterations (especially systemic bleeding and hypovolemic shock), coagulopathy and renal alterations (which could evolve into acute kidney injury) (Brasil, 2010; Guti errez et al., 2009a; Guti errez and Lomonte, 1989) . The specific treatment for bothropic envenomation is the intravenous administration of bothropic antivenom (BAv). This antivenom is produced in Brazil by hyperimmunization of horses with a pool of venoms from Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni, Bothrops alternatus and Bothrops neuwiedi snakes, with the aim of neutralizing all the Bothrops venoms distributed in this country (Brasil, 2010) . However, some previous studies have shown pre-clinical evidence that the antivenom used in Brazil may not fully neutralize the toxic activities induced by all bothropic venoms, suggesting that other venoms should be included in the immunization pool for the preparation of a universal bothropic antivenom (Muniz et al., 2000; Queiroz et al., 2008) . Many factors including phylogeny, sex, geographic origin, season, age and prey preference may influence the venom composition, which could affect the neutralizing capacity of antivenom (Chippaux et al., 1991) . Bothrops erythromelas (Amaral, 1923) , commonly known as "Caatinga lancehead", "jararaca da seca" or "jararaca malha de cascavel", is a small terrestrial venomous snake responsible for most of the snakebites in Northeastern Brazil (Lira-da- Silva et al., 2009 ). Therefore, since B. erythromelas is not included in the pool of venoms that are used in the Brazilian polyvalent bothropic antivenom production, this calls into question the efficacy of BAv.
Snake venom toxins such as metalloproteinases (SVMPs), phospholipases A 2 (PLA 2 ) and hyaluronidases are mostly responsible for the local tissue damage frequently observed in bothropic envenomation. The action of these toxins are, in general, poorly neutralized by antibodies present in antivenom, so it is well known that antivenom therapy has limited efficacy against venominduced local effects, making the search for complementary alternatives to treat snakebites an important task (Guti errez et al., 2006) . In addition to poor inhibition of local damage, there is a risk of development of immunological reactions, the high cost of production and very difficult access in some regions (Guti errez et al., 2011; Silva et al., 2015) . This inability to treat local effects, as well the increased time between accident and treatment, are the main reasons for the temporary or permanent disability observed in many victims, which can lead to serious negative social, economic, and health impacts, given that most victims live in rural areas (Guti errez et al., 2013) .
The use of medicinal plants against snakebites is a historical practice carried out throughout human history, with this knowledge being transferred down among the rural communities from generation to generation (Butt et al., 2015) . Nowadays, these herbal antidotes used in traditional folk medicine have gained much attention by toxinologists worldwide as a tool for designing potent inhibitors against snake venom toxins (Sulochana et al., 2015) . The possible advantages of a potential application of medicinal plants as antiophidic agents are that, in general, they would be cheap, easily available, stable at room temperature and could be able to neutralize a broad spectrum of toxins, including those related to the local tissue damage (Gomes et al., 2010; Santhosh et al., 2013) .
Jatropha gossypiifolia is a medicinal plant popularly known in Brazil as "pinhão-roxo" or worldwide as "bellyache-bush", and it belongs to the Euphorbiaceae family. It is largely used in folk medicine for various purposes, especially as antiophidic, antiinflammatory, anti-hemorrhagic, hemostatic and healing, amongst others (F elix- Silva et al., 2014a) . The effectiveness of the aqueous extract of this plant against enzymatic and biological effects of Bothrops jararaca snake venom has been previously demonstrated, including significant inhibitory potential against the local tissue damage induced by this venom in mice (F elix-Silva et al., 2014d) .
In this context, this study was carried out aiming two main goals: (a) to evaluate whether the polyspecific bothropic antivenom (BAv) manufactured in Brazil is effective against local effects induced by B. erythromelas snake venom (BeV), and (b) to assess the efficacy of the aqueous leaf extract of J. gossypiifolia (AE) against these effects.
Material and methods

Chemicals and reagents
Azocasein, hexadecyltrimethylammonium bromide, hyaluronic acid and o-dianisidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hydrogen peroxide was purchased from Merck (Darmstadt, HE, Germany). Agarose was purchased from Uniscience do Brasil (São Paulo, SP, Brazil) . Coomassie Brilliant Blue R-250 was purchased from Vetec Química Fina Ltda. (Duque de Caxias, RJ, Brazil). Sodium thiopental was purchased from Crist alia (Itapira, SP, Brazil). Drabkin's reagent (120 mM potassium ferricyanide, 150 mM potassium cyanide and 0.1% non-ionic detergent in 200 mM potassium dihydrogen phosphate) and hemoglobin standard solution were purchased from Bioclin (Belo Horizonte, MG, Brazil). All other reagents and solvents used were of analytical grade. The water used was purified by reverse osmosis. Phosphate buffered saline (PBS) was utilized and contained the following constituents: 137 mM NaCl, 3 mM KCl, 1.5 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , pH 7.4.
Snake venom
Venoms from Bothrops erythromelas (BeV) and Bothrops jararaca (BjV) snakes were a kind gift from Kathleen Fernandes Grego, Instituto Butantan, SP, Brazil. The venoms were obtained by manual extraction from adult specimens and then lyophilized and kept at À20 C until used. Venom solutions were prepared with PBS at time of use. The amount of venom was expressed by protein content, determined by Bradford protein assay using albumin as standard (Bradford, 1976 The leaves were dried at room temperature, triturated and stored in hermetically sealed bottles protected from light and humidity until use for extract preparation.
The collection of the plant material was conducted under authorization of Brazilian Biodiversity Authorization and Information System (SISBIO) (Process number 35017) and Brazilian Genetic Heritage Management Council (CGEN) (Process number 010844/ 2013-9).
Aqueous extract (AE) preparation
Aqueous extract (AE) from J. gossypiifolia was prepared by decoction, by extracting dried leaves with purified water to the ratio 1:10 (w/v) for 15 min at 100 C. The method of extraction was chosen based on previous literature that indicates that this is the main form of utilization in folk medicine (tea decoction) and on previous research by our group (F elix- Silva et al., 2014a Silva et al., , 2014c Silva et al., , 2014d . A yield of 13.57% (relative to dry plant) was obtained. The aqueous extract obtained after vacuum filtration was freeze-dried and dissolved in PBS at the time of use, at adequate concentrations for the biological assays.
Bothropic antivenom (BAv)
The bothropic antivenom (BAv) used was produced by the Instituto Butantan, São Paulo, SP, Brazil, from plasma of horses that had been immunized with a mixture of the following venoms: Bothrops jararaca (50%), Bothrops neuwiedi (12.5%), Bothrops alternatus (12.5%), Bothrops moojeni (12.5%) and Bothrops jararacussu (12.5%). The batch number was 135101A, and according to the label of the product, each millilitre of BAv is able to neutralize 5 mg of B. jararaca venom (reference venom) in lethality tests in mice. Swiss albino mice (about 30 g, 6e8 weeks old), from both sexes, supplied by the animal facility of Centro de Ciências da Saúde from Universidade Federal do Rio Grande Norte were used. The mice were matched by sex and age in all procedures. The animals were housed in standard polypropylene cages (30 Â 19 Â 13 cm) and maintained under controlled temperature (22 ± 2 C) in a 12 h light/dark cycle. The mice were fed with a standard laboratory extruded food (Presence ® , purchased from Agroline, Campo Grande, MS, Brazil) and water ad libitum. At the end of the experiments, the animals were euthanized by sodium thiopental overdose (100 mg/kg) by intraperitoneal (i.p.) route.
Treatment protocols and doses employed
Doses of AE and BAv were administered following two treatment protocols: pre-treatment (AE or BAv used 60 min before venom was injected) and post-treatment (AE or BAv administered 1 min after venom was injected). In both protocols, AE (400 mg/kg) or BAv (100 mL/mice) were administered by intraperitoneal route. AE doses used were based on dose-effect studies (result not shown), from where we chose the most effective one. Dose and via of administration of BAv were chosen based on pilot assays, previous studies found in literature and the actual label of the product, which indicates that 1 mL of BAv neutralizes 5 mg of B. jararaca venom (reference venom), which corresponds to a proportion of 1:0.2 BjV: BAv (w/v). Considering the challenge of doses employed in this work, an excess of BAv in relation to the label of the product was used, to avoid possible false-negative results due to low dosage of BAv (Supplementary Table 1 ). Groups where envenomed animals were treated with PBS were used as control (venom control). In addition, as negative control, animals received only PBS instead of venom and AE or BAv (health control).
Edematogenic activity
The edematogenic activity of BeV was evaluated using the paw edema model, as previously described in the literature with a few modifications (F elix- Silva et al., 2014d) . BeV (1 mg/50 mL of PBS) was injected subcutaneously into the right hind paw. Control animals received equal volume of PBS (normal control). The BeV dose was chosen based on pilot assays, where the selected dose induced significant paw edema without producing paw hemorrhage. The individual right hind paw thickness was measured immediately before venom injection (basal value) and at selected time intervals after edema induction (0.25, 0.5, 1, 1.5 and 2 h), using a digital caliper (Digimess, São Paulo, SP, Brazil). Edema was expressed as the percentage difference between the thickness of the paw after (at respective time points) and before (basal values) venom injection, as mean ± standard error of mean, with n ¼ 5 animals per group. In addition, the area under the time-course curve after 2 h (AUC 0e2h ) was calculated using trapezoidal rule.
After 2 h of BeV injection, the animals were euthanized and their right hind paws were collected for quantification of myeloperoxidase (MPO) enzyme activity, as a biochemical marker of neutrophil migration to the inflammation site, as previously described (Bradley et al., 1982) . Briefly, paw skin tissues were weighed, chopped and homogenated in 0.5% hexadecyltrimethylammonium bromide buffer (1 mL of buffer for each 50 mg of tissue). Then, samples were sonicated in an ice bath for 30 s, submitted to three freeze-thaw cycles and finally sonicated for 30 s once more, for MPO enzyme extraction. The supernatant obtained after centrifugation at 10,000 g for 10 min at 4 C was used for MPO activity determination, by mixing 20 mL of each supernatant with 200 mL of 50 mM potassium phosphate pH 6.0 containing 0.0005% hydrogen peroxide and 0.167 mg/mL o-dianisidine. The measurement of the activity was carried out at 460 nm using a microplate reader (Epoch-Biotek, Winooski, VT, USA), through kinetic reading at 1 min intervals, during 3 min. One unit of MPO is defined as the equivalent to the consumption of 1 mmol of hydrogen peroxide per minute, considering that 1 mmol of hydrogen peroxide gives a change in absorbance of 1.13 Â 10 À2 per minute (Posadas et al., 2004) . Samples of each animal were analysed in triplicate and the mean of these determinations was used to express the result as mean ± standard error of mean, with n ¼ 5 animals per group.
Hemorrhagic activity
The hemorrhagic activity of BeV was evaluated using the local skin hemorrhage model, as previously described in the literature, with a few modifications (Domingos et al., 2015; Roodt et al., 2000) . BeV (25 mg/100 mL of PBS) was injected subcutaneously in the central region of the abdomen of mice. Control animals received equal volume of PBS (normal control). After 3 h, the animals were sacrificed and the inner surface of the skin was exposed. The hemorrhagic skin was excised out and weighed on an analytical balance. The hemorrhage was expressed as the mass of hemorrhagic halo formed after subcutaneous injection of venom, in grams, as mean ± standard error of mean, with n ¼ 5 animals per group.
Thereafter, the hemorrhagic skin was fragmented and homogenized with 3 mL of Drabkin's reagent for hemoglobin extraction. After incubation for 48 h at 8 C, the samples were firstly centrifuged at 392 g for 10 min, at room temperature. Then, 1 mL of this supernatant was centrifuged at 16,000 g for 30 min, at 4 C. Finally, the clear supernatant obtained was read at 540 nm in a microplate reader (Epoch-Biotek, Winooski, VT, USA), using Drabkin's reagent as blank. The hemoglobin content in excised hemorrhagic halo was determined through a standard curve using hemoglobin. The hemorrhage was expressed as the hemoglobin content extracted from excised hemorrhagic halo formed after subcutaneous injection of venom, in mg/mL. Samples of each animal were analysed in triplicate and the mean of these determinations was used to express the result as mean ± standard error of mean, with n ¼ 5 animals per group.
In vitro enzymatic assays 2.6.1. AE and BAv pre-incubation
For inhibition studies, a fixed amount of BeV was pre-incubated for 30 min at 37 C with varying amounts of AE or BAv. Then, the venom þ antivenom mixtures were submitted to enzymatic assay as described below. For phospholipase A 2 (PLA 2 ) and proteolytic activities, the 1:25, 1:50 and 1:100 BeV: AE (w/w) ratios were employed, while in hyaluronidase activity, the ratios used were 1:1, 1:2.5 and 1:5 (w/w). For BAv inhibitory evaluation, in all enzymatic tests performed, the ratios BeV: BAv (w/v) 1:0.25, 1:0.5 and 1:1 were used (Supplementary Table 1 ). As in the in vivo studies, considering the challenge doses employed in this work, there is an excess of BAv to avoid possible false-negative results due to low dosage of BAv, as explained in Supplementary Table 1. Tubes where AE or BAv were substituted for PBS (ratio 1:0, BeV: antivenom, w/v) were used as control (venom control).
Proteolytic activity upon azocasein
Proteolytic activity of BeV was determined colorimetrically using azocasein as substrate, as previously described in the literature, with some adaptations (Pereañez et al., 2013) . For the assay, 15 mg of BeV were pre-incubated for 30 min at 37 C with different concentrations of AE or BAv in PBS, at a final volume of 100 mL. Then, in each tube, 100 mL of azocasein (10 mg/mL in 50 mM Tris-HCl pH 7.4 buffer containing 200 mM NaCl and 5 mM CaCl 2 ) was added and incubated for 90 min at 37 C. The enzymatic reaction was stopped by adding 100 mL of 5% trichloroacetic acid. After 30 min standing at room temperature, the tubes were centrifuged at 15,000 g for 10 min at 22 C. The supernatant (100 mL) was removed and mixed with equal volume of 0.5 M NaOH in a 96-well microplate. After 10 min at room temperature, the samples were read at 440 nm in a microplate reader (Epoch-BioTek, Winooski, VT, USA). Blanks for each concentration of AE or BAv were prepared the same way, except by adding the substrate only after trichloroacetic acid addition. The proteolytic activity was calculated as the percentage of degradation products of azocasein formed, taking into account the absorbance increase compared to the control in which only substrate was incubated (absence of venom, AE and/or BAv). The results were expressed as percentage of proteolytic activity in relation to control in which only BeV was incubated (absence of AE or BAv, considered 100% of proteolytic activity), as mean ± standard error of mean, with n ¼ 3.
2.6.3. Phospholipase A 2 (PLA 2 ) activity PLA 2 activity of BeV was determined turbidimetrically in 96-well microplates using an egg yolk suspension as substrate, as previously described in the literature, with some adaptations (Liu et al., 2015; Marinetti, 1965) . First, egg yolk was mixed with PBS in a 1:3 (v/v, egg yolk: PBS) ratio, and then centrifuged at 400 g for 2 min at room temperature to obtain in the supernatant the stock suspension of egg yolk. Before the assay, the substrate concentration was determined as that which gives an absorbance of 0.6 at 925 nm, which was a 5% dilution of the stock suspension of egg yolk in 50 mM Tris-HCl pH 7.4 buffer containing 200 mM NaCl and 5 mM CaCl 2 . For the assay, 100 mL of this suspension was mixed with 100 mL of a solution containing 2.5 mg of BeV pre-incubated for 30 min at 37 C with different concentrations of AE or BAv in PBS. Blanks for each concentration of AE or BAv were prepared similarly, except for replacing the substrate with an equal volume of assay buffer. After 30 min at 37 C, the absorbance was read at 925 nm, using a microplate reader (Epoch-BioTek, Winooski, VT, USA). The PLA 2 activity was calculated as the percentage of remaining substrate, taking into account the turbidimetric decrease compared to the control in which only substrate was incubated (absence of venom, AE and/or BAv). The results were expressed as percentage of PLA 2 activity in relation to control in which only BeV was incubated (absence of AE or BAv, considered 100% of PLA 2 activity), as mean ± standard error of mean, with n ¼ 3.
Hyaluronidase activity
Hyaluronidase activity of BeV was determined turbidimetrically in 96-well microplates using hyaluronic acid as substrate, as previously described in the literature, with some adaptations (Paixão-Cavalcante et al., 2015) . The assay mixture contained acetate buffer (0.2 M sodium acetate pH 6.0 containing 0.15 M NaCl), 10 mg of hialuronic acid (0.5 mg/mL in acetate buffer) and 3 mg of BeV preincubated for 30 min at 37 C with different concentrations of AE or BAv in PBS, in a final volume of 100 mL. Blanks for each concentration of AE or BAv were prepared similarly, except for replacing the substrate with an equal volume of assay buffer. This mixture was incubated for 60 min at 37 C and then the enzymatic reaction was stopped by adding 200 mL of 2.5% hexadecyltrimethylammonium bromide buffer in 2% sodium hydroxide. After 10 min at room temperature, the absorbance was read at 925 nm, using a microplate reader (Epoch-BioTek, Winooski, VT, USA). The hyaluronidase activity was calculated as the percentage of remaining substrate, taking into account the turbidimetric decrease compared to the control in which only substrate was incubated (absence of venom, AE and/or BAv). The results were expressed as percentage of hyaluronidase activity in relation to control in which only BeV was incubated (absence of AE or BAv, considered 100% of hyaluronidase activity), as mean ± standard error of mean, with n ¼ 3.
Ouchterlony double immunodifusion test
Comparison of BeV and BjV antigens
BAv cross-reactivity was investigated by double immunodifusion test, as previously described (Ouchterlony, 1953) . B. jararaca venom (BjV), which is the main antigen present in the pool of immunization for BAv production (comprises 50% of antigenic mixture) was used for comparison. Briefly, 1% agarose was prepared in PBS, heated, poured into a clean glass Petri dish and allowed to solidify, producing a 3 mm thick gel. Using a template, three wells (5 mm) were punched 10 mm apart, forming an equilateral triangle.
In the central well, 15 mL of BAv was applied, while in the peripheral wells 15 mL of solutions of BeV and BjV (1 mg/mL, each one) were used. The plates were then incubated at 37 C in a humidified chamber overnight, so as antigen-antibody complexes formed by immunodifusion. The positive results were taken as the presence of precipitin lines between BAv and each venom. The pattern of lines formed was classified by pattern of identity, partial identity or nonidentity, to evaluate the similarity between BeV and BjV and their possible cross-reactivity.
Antibody titers estimation
The titers of antibodies against BeV and BjV were determined using serial dilutions of BAv and a double immunodifusion test as previously described, with a few adaptations (Lanari et al., 2014) . Agarose gels were prepared as described above. Using another template, six wells (5 mm) were punched 10 mm apart, forming a regular hexagon. In a seventh well, located in the centre of the hexagon, 15 mL of BeV or BjV (1 mg/mL) was applied, while in the sixth peripheral well 15 mL of serial dilutions of BAv (1/1 to 1/32) were placed. The plates were then incubated at 37 C in a humidified chamber, overnight. To increase technique sensitivity, after developing the precipitin bands, the gels were removed from the Petri dishes to be washed 3 times for 15 min with 0.1 M NaCl solution, then dried at 37 C for 60 min, and stained with 0.3% Coomassie Brilliant Blue R-250 (in 40% methanol and 10% acetic acid solution) for 5 min. After washing in destaining solution (35% methanol and 10% acetic acid), gels were dried in air and photo documented. The antibody titers against BeV and BjV venoms were defined as the reciprocal of the highest dilution of antivenom giving a positive precipitin band.
Data analysis
All results are presented as mean ± standard error of mean (SEM). One-way ANOVA followed by Tukey's test or Two-way ANOVA followed by Bonferroni's test were performed using GraphPad Prism version 5.00 (San Diego, CA, USA). P values less than 0.05 were considered significant.
Results
Inhibition of edematogenic activity by AE and BAv
The edematogenic activity of BeV was almost completely inhibited (about 90% of inhibition) by AE 2 h after venom injection in mice paws (P < 0.001), when this extract was administered before venom injection (Fig. 1, Supplementary Table 2 ). This result was very similar to that of BAv, also administered before BeV. However, in the post-treatment protocol only AE was effective, inhibiting about 67% of BeV edema at 2 h (P < 0.001), while BAv did not reach statistical significance after 2 h of edema observation (P > 0.05). As observed in Fig. 1A and Supplementary Table 2, in pretreatment protocol, AE reached a significant inhibitory percentage (66.3%) as quickly as 15 min (P < 0.001), while in post-treatment, as expected due to pharmacokinetic reasons, a lower inhibition percentage was observed (42.8%), although also statistically significant (P < 0.001). Also as shown in Fig. 1A and Supplementary Table 2, it could be observed that BAv reached significant (P < 0.01) inhibitory percentage (40.2%) at 15 min, when administered before venom. However, when the post-treatment protocol was used, no inhibitory activity was observed; only at the end of the period of observation (about 1.5e2 h after envenomation) could be observed a small extent of inhibition, but this did not reach statistical significance (P > 0.05).
Considering the total edema effect, calculated by the area under the time-course curves after 2 h (AUC 0e2h ) values (Fig. 1B) , it could be observed that while in pre-treatment protocol both AE and BAv were active, when treatment was given after envenomation only AE was active (P < 0.001).
A similar behaviour was also observed regarding the myeloperoxidase (MPO) extracted from the mice paws, i.e. both AE (P < 0.001) and BAv (P < 0.01) were active in pre-treatment protocol, inhibiting about 70 and 42%, respectively (Table 1) ; but only AE presented statistically significant anti-inflammatory activity when dosed after envenomation (P < 0.001, about 63% of inhibition) (Fig. 2) . However, while pre-treatment with BAv diminished the paw edema, this did not occur with MPO activity, as it did not reach statistical significance (P > 0.05), indicating that this inflammatory parameter was not really influenced by BAv treatment.
Inhibition of local hemorrhagic activity by AE and BAv
The hemorrhagic activity of BeV was partially inhibited by AE and BAv (shown in Fig. 3 and Table 1 ). In general, AE, in both pre and post-treatment protocols, showed similar results in relation to BAv when used prior to envenomation. As observed for edematogenic activity, BAv when administered after BeV injection did not produce a statistically significant inhibitory effect (P > 0.05).
Two parameters were used to evaluate BeV-induced skin hemorrhage: hemorrhagic halo weight and hemoglobin content from these haloes. Regarding hemorrhagic halo weight (Fig. 3A) , AE in both protocols presented similar inhibitory percentages (about 41%), with different significance levels (P < 0.01 and P < 0.001 for Fig. 1 . Inhibition of edematogenic activity of Bothrops erythromelas venom (BeV) by aqueous extract (AE) of Jatropha gossypiifolia and bothropic antivenom (BAv). (A) Timecourse of paw edema. **P < 0.01 and ***P < 0.001, when compared to the BeV control group in two-way ANOVA followed by Bonferroni's test. (B) Area under the timecourse curves after 2 h (AUC 0e2h ) values. ***P < 0.001, when compared to the BeV control group in one-way ANOVA followed by Tukey's test. Data showed as mean ± SEM (n ¼ 5/group).
pre-and post-treatment protocols, respectively). BAv, in pretreatment protocol, inhibited almost 50% of hemorrhagic halo weight, thus being a little bit more active than AE, although this difference was not statistically significant (P > 0.05). However, in post-treatment protocol, BAv inhibited only about 26% of hemorrhagic halo weight, and did not reach statistical significance (P > 0.05).
When evaluating the extracted hemoglobin content from the hemorrhagic haloes (Fig. 3B) , similar results were observed (Table 1) . AE was active in both treatment protocols, however, interestingly, AE was a little bit more active when administered after envenomation (P < 0.01, 41.9% of inhibition), than when it was used before venom application (P < 0.05, 30.8% of inhibition); however, this difference between treatment protocols was not statistically significant (P > 0.05). The same as what occurred in hemorrhagic halo weight, BAv in pre-treatment protocol decreased the hemoglobin content in 52.3% (P < 0.001), but did not reach statistical significance in the post-treatment protocol (P > 0.05), although it did achieve an inhibitory potential of almost 25% of the hemoglobin content (Table 1) .
Inhibition of enzymatic activities by AE and BAv
AE was able to inhibit significantly the proteolytic (Fig. 4A) , PLA 2 (Fig. 4B) and hyaluronidase (Fig. 4C ) activities of BeV. For PLA 2 and hyaluronidase activities, the inhibition percentage reached 100%. Proteolytic activity was not totally inhibited but reached up to 83% of inhibition.
BAv, on the other hand, was able to inhibit completely only the hyaluronidase activity of BeV (Fig. 5C ), while PLA 2 activity was inhibited only partially (up to about 16% of inhibition) (Fig. 5B) and there was no inhibition of proteolytic activity (Fig. 5A) , even using much higher BeV: BAv ratios than necessary, according to those indicated on the BAv product label (Supplementary Table 1) .
BAv cross-reactivity and antibody titers against BeV and BjV
Cross-reactivity between BAv and BeV and BjV was measured by agarose gel immunodifusion, in which precipitin bands were observed against both Bothrops venoms. A complete identity pattern was observed for BeV and BjV, which indicates the presence of common antigenic determinants in these venoms. When determining the antibody titers of BAv against each venom, the maximum dilution of antivenom in which immunoprecipitation lines were observed were 1:16 for BeV and 1:32 for BjV, suggesting a slightly higher antibody titer against BjV. In addition, some minor precipitin bands between practically all dilutions of BAv against BjV were observed, while against BeV this was only observed in lower dilutions of BAv. Table 1 Summary of inhibition percentages of aqueous extract of Jatropha gossypiifolia (AE) and bothropic antivenom (BAv) against edematogenic and hemorrhagic local effects induced by Bothrops erythromelas venom (BeV) in vivo.
Treatment
Protocol Edematogenic activity Hemorrhagic activity AUC 0e2h MPO activity Halo weight Hemoglobin AE Pre-treatment 72.9 ± 3.2*** 69.2 ± 12.5*** 40.8 ± 5.1** 30.8 ± 5.5* Post-treatment 50.2 ± 6.2*** 63.0 ± 8.6*** 42.7 ± 10.1*** 41.9 ± 11.2** BAv Pre-treatment 73.0 ± 2.1*** 41.6 ± 1.6*** 48.1 ± 4.4*** 52.3 ± 8.3*** Post-treatment 17.4 ± 8.9 30.4 ± 6.9 26.2 ± 8.0 24.9 ± 2.6 AUC 0e2h : area under time-course after 2 h. MPO: myeloperoxidase. Data show mean ± SEM (n ¼ 5/group). *P < 0.05, **P < 0.01 and ***P < 0.001, when compared to BeV control group in one-way ANOVA followed by Tukey's test. Inhibition percentage calculated as follows: [1 e (%Activity test e %Activity PBS control mean ) ÷ (%Activity BeV control mean e % Activity PBS control mean )] Â 100. Fig. 2 . Effect of aqueous extract (AE) of Jatropha gossypiifolia and bothropic antivenom (BAv) on myeloperoxidase (MPO) activity in mice paws injected with Bothrops erythromelas venom (BeV). ***P < 0.001, when compared to the BeV control group in oneway ANOVA followed by Tukey's test. Data showed as mean ± SEM (n ¼ 5/group). Weight of hemorrhagic haloes formed after subcutaneous injection of BeV in mice skin after 3 h. (B) Hemoglobin content in hemorrhagic haloes obtained in (A). *P < 0.05, **P < 0.01 and ***P < 0.001, when compared to the BeV control group in one-way ANOVA followed by Tukey's test. Data showed as mean ± SEM (n ¼ 5/group).
Discussion
B. erythromelas venom (BeV) is not included in the antigenic pool for production of bothropic antivenom (BAv) distributed in Brazil, which puts into question the efficacy of the national antivenom against this venomous species of high incidence in Northeastern Brazil. In this context, and taking into account previous studies in mice showing the potentiality of J. gossypiifolia aqueous leaf extract as an antiophidic agent (F elix- Silva et al., 2014d) , this study aimed to evaluate the inhibitory potential of the aqueous extract (AE) of this vegetal species against local effects induced by BeV, as well as to assess whether the polyspecific bothropic antivenom (BAv) manufactured in Brazil is effective against these effects.
In the present work, two treatment protocols were used for in vivo experiments. The pre-treatment protocol (treatment before venom injection) is relevant since it ensure that there are bioavailable compounds in circulation at the time of envenoming, thus avoiding the obtainment of false-negative results due the very rapid onset of local effects induced by snake venom. On the other hand, the post-treatment protocol (treatment after envenomation) aimed to simulate the practical clinical use of the products as curative remedies for snake envenoming, since it mimics more closely the real practical use of antivenom and show the efficacy of the compounds when the poisoning is already more or less established (since until the products are absorbed, the venom has already begun to produce its toxic effects).
A summary of inhibition percentages of AE and BAv against BeVinduced local effects in these treatment protocols is shown in Table 1 . In vivo, AE was significantly active in both treatment protocols, while BAv was active only in the pre-treatment protocol. These results were corroborated with the in vitro enzymatic assays, where BAv was poorly active against proteolytic and PLA 2 activities, being active only against hyaluronidase activity of BeV (Fig. 5) , while AE was able to inhibit all the enzymatic activities tested, reaching 100% of inhibition in most of the cases (Fig. 4) .
Bothropic envenomation is characterized by the rapid development of an inflammatory process at the site of venom injection. The pathophysiology of edema formation is multifactorial, involving direct action of venom components on the microvasculature, increasing of the permeability of capillaries and venules, and the effect of endogenous mediators released by venom components, such as histamine, prostaglandins, kinins and activated products from the complement system (Guti errez and Lomonte, 1989; Guti errez et al., 2009b) . This response often causes severe edema, ischemia and neural compression, which may result in a compartmental syndrome that can lead to permanent loss of tissue or amputation of the affected limb due to necrosis (Teixeira et al., 2009) .
In general, it was observed that AE and BAv presented higher inhibitory effect when used before venom than when used after. This could be expected since in pre-treatment both AE and BAv have more time to be absorbed into circulation and thus be distributed. In post-treatment protocol, on the other hand, only AE was significantly active. A possible justification for this poor action of BAv is the fact that antivenom neutralizes toxins, but cannot neutralize the action of the subsequently released endogenous inflammatory mediators. In fact, an early study shows that local effects induced by some Bothrops species are poorly neutralized by commercial antivenoms when they were administered right before envenomation by intravenous route (Picolo et al., 2002) . Another study, evaluating the efficacy of bothropic antivenom on microcirculatory effects induced by B. jararaca snake venom, showed that the antivenom therapy has low effectiveness against these effects due to impaired and delayed venom and antivenom interaction at the site of injury due local events caused by the venom (Battellino et al., 2003) . In addition, it is important to emphasize that additional experiments administering BAv by intravenous route (instead of intraperitoneal route) showed similar results, excluding thus the influence of the via of administration in the low efficacy of BAv against BeV (data not shown).
Based on the inhibitory action of AE against PLA 2 activity of BeV (Fig. 4) , the action via inhibition of this class of toxins may be highlighted, since prior studies showed a significant positive correlation of edematogenic activity of some Bothrops venoms with PLA 2 activity in vitro (Souza et al., 2015) . Another possibility may be an inhibitory action upon SVMPs, since the extract also presented anti-hemorrhagic effect (Fig. 3) and inhibited proteolytic activity of BeV (Fig. 4) . SVMPs play a relevant role in the prominent local inflammatory response, since they induce edema, activate endogenous matrix metalloproteinases and are capable of releasing TNF-a from its membrane-bound precursor (Guti errez and Rucavado, 2000) . In addition, the role of the inhibition of hyaluronidase activity in the antiedematogenic activity of AE must be pointed out. Hyaluronidases, popularly known as "spreading factors", generally acts upon hyaluronic acid from the extracellular matrix (ECM) of soft connective tissue, weakening the structural integrity of ECM by degrading hyaluronic acid and facilitating the easy diffusion of the toxins (Kemparaju and Girish, 2006) . The degraded products of hyaluronic acid are described as damage-associated molecular patterns (DAMPs) and are immunostimulatory and proinflammatory in nature, triggering several inflammatory pathways and increasing the expression of pro-inflammatory cytokines such as TNF-a, IL-1b and IL-6, aggravating inflammation (Sunitha et al., 2015) . BAv, in the present work, also inhibited completely the hyaluronidase activity from BeV, but this inhibition was insufficient to inhibit completely the local edematogenic effect of this venom, since it involves the participation of several toxins besides hyaluronidases, as discussed above.
Besides its action upon snake venom toxins, the antiedematogenic activity of AE may be attributed to the indirect action of the extract upon endogenous inflammatory mediators released by venom toxins. Indeed, some studies have shown that antiinflammatory and/or antioxidant drugs could inhibit the inflammatory response against Bothrops venoms (Araújo et al., 2007; Sunitha et al., 2015) . Previous studies with AE have shown significant anti-inflammatory and antioxidant activities in this plant (F elix-Silva et al., 2014b (F elix-Silva et al., , 2014c . In this context, the use of antiophidic plants as adjuvants in antivenom therapy is interesting due to their potential ability to neutralize a broad spectrum of toxins and greatly inhibit local tissue damage due to an indirect action towards endogenous mediators.
Hemorrhage is one of the most characteristic effects induced by Bothrops venoms. The local hemorrhage is associated with the action of hemorrhagic SVMPs, also called hemorrhagins, which cause proteolysis of basal lamina components of microvessels, with loss of vascular wall integrity, leading to blood extravasation to skin (Guti errez et al., 2016; Guti errez and Lomonte, 1989) . As observed in Fig. 3 , AE presented very similar results in both treatment protocols. BAv, as occurred in the paw edema model, was active only when used before venom. The inhibitory action of AE could be explained by its significant inhibitory potential against proteolytic activity of BeV, which suggests an inhibitory action against SVMPs (Fig. 4) . BAv, by the other hand, was not able to inhibit the in vitro proteolytic activity of BeV upon azocasein, which could justify the low effectiveness of this antivenom against hemorrhagic activity of BeV. However, owing to the known cross-reactivity of viperid snake venom proteinases, this lack of neutralization was surprising. So, additional experiments using a different substrate (fibrinogen) were performed and visualized by polyacrylamide gel electrophoresis (SDS-PAGE), according to previously described (F elix -Silva et al., 2014d) . In these experiments, it was observed some extent of neutralization of proteolytic activity only at higher levels of BAv, which indicates that BAv can neutralize, at least partially, some proteinases from BeV (data not shown).
The general low potency of BAv against BeV observed in this work may be related with the fact that BeV is not included in the antigenic mixture for production of this antivenom in Brazil. Despite the broad cross reactivity of the epitopes that are shared between the snake venom toxins, the existence of particular components in each venom may result in an antivenom with poor neutralizing activity coverage. So, to assess how much BAv can recognize immunologically BeV, the Ouchterlony double diffusion test was employed.
According to our experiments, precipitin lines were observed against both BeV and BjV, thus indicating immunological recognition of both venoms. In addition, a slightly higher antibody titer against BjV was suggested, since precipitin lines were still observed in a slightly higher antivenom dilution when compared to BeV. Owing the low effectiveness of BAv against BeV, this result may indicate the presence of highly immunogenic components in BeV, which are toxicologically non-relevant for the toxic venom action, which could justify the presence of immunological recognition with little neutralizing potential. Interestingly, Muniz et al. (2000) , while analyzing the effectiveness of BAv against some Amazonian Bothrops species, observed that the immunological reactivity against BjV was higher than against other Bothrops venoms and that this antivenom, in general, failed to inhibit the lethal, hemorrhagic and PLA 2 activities of Bothrops venoms from the Amazonian rain forest (Muniz et al., 2000) .
Using different experimental protocols, some other works have also shown the low efficacy of BAv against BeV. Bezerra (2000) showed that BAv was less active than a monoespecific BeVantisera against several enzymatical and biological activities of BeV, and presented a poor capacity to form immunocomplexes, indicating the low cross-reactivity between B. erythromelas and the other Bothrops species used for BAv production. In another work, it was observed that BAv was less active against BeV when compared to BjV (Castro Junior, 2008) . Queiroz et al. (2008) showed by ELISA that BAv presented only intermediate antibody titers for BeV, when compared to the venoms used for BAv production and, interestingly, observed that BAv was able to neutralize significantly only the hyaluronidase activity of BeV (about 65% of inhibition), while proteolytic and PLA 2 activities were not.
Regarding the J. gossypiifolia plant, in previous studies conducted by our group, chromatographic analysis of AE showed the presence of alkaloids, terpenes, steroids, phenolic compounds, flavonoids, tannins, amines and sugars (F elix-Silva et al., 2014c) . From these, flavonoids may be highlighted, since they seem to be the leading compounds of the aqueous leaf extract of the plant (F elix- Silva et al., 2014c) . Studies are being carried out in our lab aiming to isolate and evaluate the bioactivity of these phytoconstituents. Regarding safety, previous results from our group showed that AE did not present hemolytic nor cytotoxic action against HEK-293 cells, suggesting the low toxicity of this plant extract (F elix- Silva et al., 2014c) .
In conclusion, the data presented in this work indicate that despite the presence of some extent of immunological crossreactivity, Brazilian polyvalent bothropic antivenom presented poor inhibitory potential against biological and enzymatic effects induced by B. erythromelas snake venom, illustrating the need for new strategies in the production of antivenoms with broad neutralizing potential in the treatment of bothropic envenomation throughout the country. Together, the results highlight the antiophidic potential of J. gossypiifolia aqueous leaf extract, suggesting that it can be considered as a potential future adjuvant in the treatment of bothropic envenomation local effects.
